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A 38-year-old male required the initiation of regular hemodialysis
treatment 19 years ago because of end-stage renal disease due to
mesangioproliferative glomerulonephritis.
After an initial 3 months of center dialysis, during which an arterio-
venous fistula was created in the left forearm, the patient was trained
for home dialysis. At home, he was dialyzed overnight 3 x 10
hours/week at a blood flow of 250 mI/mm and a dialysate flow of 500
mi/mm using the Klll dialyzer with cellulosic membranes and a 1 m2
surface area; a given dialyzer was used three times before being rebuilt.
After 5 years, "reuse" KiiI dialysis was replaced by single-use dialysis
employing a 1 m2 commercial plate dialyzer with cellulosic membranes;
dialysis time was reduced to 3 x 8 hours/week but blood and dialysate
flow rates were unchanged. At that time the patient was totally anuric.
His predialysis (first dialysis of the week) serum urea and creatinine
concentrations with the new dialysis regime ranged from 2 1—25 mmol/
liter (120—150 mg/dl) and 1000—1100 mol/liter (11—12 mg/dl), respec-
tively. The patient was unemployed but physically well; he refused to
be placed on the walting list for cadaveric transplantation.
Ten years after the start of hemodialysis, radiologic examination of
the skeleton showed general osteoporosis without specific lesions
attributable to renal osteodystrophy. The serum levels of C-terminal
PTH were moderately elevated. The patient was normocalcemic and
had intermittent mild hyperphosphatemia (< 6 mg/dl). Bone histology
from an iliac crest biopsy revealed only slight osteitis fibrosa, as well as
minor evidence of defective mineralization. The dose of oral phosphate
binders and oral calcium carbonate was increased, and treatment with
calcitriol (0.25 pg/day) was initiated.
In the following years, clinical and neurophysiologic signs of carpal-
tunnel syndrome developed and increased in intensity; 13 years after
the start of hemodialysis, bilateral carpal-tunnel release procedures
were required for relief of symptoms. Light and electron microscopy
examination of the excised tissue showed synovial amyloid deposits
with positive immunoperoxidase staining for J2 microglobulin in the
right carpal tunnel. Histologic search for amyloid in tissue obtained
from the left carpal tunnel was negative. In both carpal tunnels,
synovial collagen was massively increased. Skeletal radiography per-
formed at the time of the operation showed small cystic lesions in both
radial heads, a single cyst in the left navicular bone, several cystic
trnnslucencies with a maximal diameter of 1.5 cm in both femoral
heads, and one juxtaarticular cyst in the right os acetabulum.
Subsequently, increasing pain and limitation of movement in both hip
joints developed; 16 years after the start of hemodialysis, the patient
could walk only with the help of crutches because of severe pain in the
left hip. Radiography revealed fractures of both femoral necks (left side,
complete; right side, incomplete) in areas of cystic transformation.
Bilateral total hip replacement was performed. Histologic examination
disclosed masses of $2 microglobulin-related amyloid within the syno-
via as well as in cystic bone lesions. In comparison with the histologic
findings on an iliac crest biopsy obtained 6 years earlier, the extent of
osteitis fibrosa had increased; staining for aluminum was negative.
Postoperatively, the daily calcitriol dose was increased to 0.5 jig.
Dialysis was performed with a 1.2 m2 polysulfone capillary membrane
at a weekly dialysis prescription of 3 x 6 hours. The j32-microglobulin
concentrations decreased from an average predialysis level of 45
mg/liter (during dialysis with the cellulosic membrane) to an average of
30 mg/liter.
One year later, the patient developed hypercalcemia, which persisted
after calcitriol therapy was stopped. At the same time, serum alkaline
phosphatase activity started to rise and C-terminal PTH was found to be
extremely high; subtotal parathyroidectomy was performed.
During his 19th year of hemodialysis, the patient began to experience
severe pain in the upper cervical vertebrae, which was induced by
movements of the neck and which spread to both shoulders and upper
arms. Radiography showed massive destruction of the arcus of the
second cervical vertebra and cystic lesions of the third cervical vertebra
(Fig, I). A nuclear magnetic resonance scan revealed nodular masses
with reduced signal intensity overlying destroyed areas of the right
lateral pnrts of the second and third cervical vertebrae (Fig. 2). These
findings were interpreted as consistent with amyloid deposits. There
was no indication of spinal cord compression.
The risks of cord damage from neurosurgical intervention were
unacceptable to the patient so that no operative procedure to stabilize
the cervical vertebrae was performed. He was provided with an
external stabilizing cravatte to prevent palnful and dangerous move-
ments. Now in his 19th year after hemodialysis, the patient has
expressed willingness to receive a renal transplant and has been placed
on a wailing list for a cadaveric graft.
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were found in the carpal synovia and perineural tissue in
long-term, regular hemodialysis patients with CTS [1—4], and in
1985 when Gejyo et al demonstrated that the lesions contained
a new type of amyloid with beta-2-microglobulin (f32m) as the
constituent protein [5, 61. Because f32m amyloidosis associated
with osteoarticular pathology appeared to be limited to the
dialysis population, the term dialysis-related amyloidosis
(DRA) was introduced.
The specific histologic diagnosis of 132m amyloid depends on
immunohistochemistry, because, like all types of amyloid, it
exhibits nonspecific Congo-red staining with green birefrin-
gence under polarized light; /32m amyloid deposits stain specif-
ically with anti-132m antibodies [5, 6]. Also like other types of
amyloid [7], /32m amyloid deposits contain serum amyloid P
(SAP) component [8] and therefore also stain with anti-SAP-
antibodies [9]. Electron microscopy reveals, in contrast to the
straight, longer, and thinner fibrils seen in other types of
amyloid, shorter and thicker curvilinear fibrils aligned in paral-
lel and aggregated in bundles [10—13].
Clinical observations
Fig. 1. The arcus of the 2nd cervical vertebra is nearly destroyed by a
large cyst (arrow). The arcus of the 3rd vertebra shows a number of
small cysts. In addition the dorsal part of the atlas is significantly
narrowed.
exemplifies a common clinical syndrome in patients with end-
stage renal disease (ESRD) who survive for 10 or more years
with regular dialysis treatment (RDT). This syndrome—dialy-
sis-related amyloidosis—with its crippling consequences, is
now recognized as a very serious complication of RDT, one that
in fact may limit the duration of long-term RDT.
During the last decade, clinical investigators gradually real-
ized that the syndrome might have no direct relationship with
established pathogenetic mechanisms of osteoarticular disease
in RDT such as secondary hyperparathyroidism or aluminum
accumulation, but that it could have a specific pathogenesis of
its own. This hypothesis was confirmed when amyloid deposits
Carpal-tunnel syndrome and destructive arthropathy associ-
ated with cystic bone lesions are the major clinical manifesta-
tions of DRA [1—4, 6, 13—23]. Although some clinical studies
[1—4, 12, 14, 15, 18, 19] of the then-putative entity were
performed before Gejyo demonstrated that f32m was the amy-
bid precursor protein [5, 6], it seems justified to attribute the
reported cases also to f32m amyboidosis because the radiologic
and clinical findings were indistinguishable from those reported
in well-established cases of J32m amyloidosis and because none
of the established causes of other types of amyboidosis was
found.
The main clinical symptoms and electrophysiologic findings
of carnal-tunnel syndrome in dialysis patients are identical to
those of idiopathic CTS and CTS accompanying other diseases
such as rheumatoid arthritis, old fractures, and diabetes melli-
tus; these symptoms and findings include hypesthesia, hypal-
gesia as well as pain (especially at night), thenar weakness and
wasting, decreased motor nerve conluction velocity, and pro-
longation or absence of distal moto latency. In hemodialysis
patients, simultaneous or successi)e bilateral occurrence of
CTS is very common. In severe cases of CTS in regular
hemodialysis patients, contraction of the hand and atrophy of
the digital muscles—the so-called "amyloid hand"—can de-
velop.
The occurrence of CTS in patients undergoing RDT was
known before the association between CTS and 132m amyloid
deposits in the carpal tissue was recognized [24, 25], but the
reported incidence of CTS increased in the years following the
discovery of f32m amyloidosis. This increase might have been
due to stimulated interest and better diagnosis, but it is also
possible that it reflected the increasing number of patients with
longer duration of RDT. In a recent study in a large population
of RDT patients, the percentage of patients who required
operation for CTS increased steeply from almost zero before 8
years of regular hemodialysis to 50% at 14 years and 100% at 20
years [26]. In one multicenter retrospective study, age at the
onset of dialysis correlated significantly with the development
of CTS [27].
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Fig. 2. TI weighted axial magnetic resonance image. Right-sided destruction of the lateral parts of the second and third cervical vertebra is
apparent. The low-signal area (arrow) in place of the destructive lesion is compatible with an amyloid deposit ( marks spinal channel with myelon).
There is considerable variation in the number of amyloid-
positive cases of CTS and in the mass of amyloid found in the
carpal tissue. Whereas in some studies 70% to 100% of the
operated cases were amyloid positive [3, 4, 21], other studies
reported a lower incidence of amyloid-positive eases [14, 15,
18]. These differences might be explained in part by differences
in the methods or thoroughness of investigation, but they also
could be interpreted as indicating pathogenetic mechanisms
other than amyloidosis. This latter interpretation is supported
by the observation that the amyloid deposits in some patients
with CTS are scattered, patchy, and minute islets within
hyperplastic connective tissue [16, 17]. Nevertheless, in other
studies the amyloid deposits were so massive that they alone
could account for median nerve entrapment [6, 28, 29].
In CTS, amyloid usually is deposited in the carpal synovia,
finger flexor tendon sheaths, transverse carpal ligament, and
perineural tissue [29, 30]. Histologically one finds a pericollag-
enous distribution of the deposits [12, 17] associated with
hyperplasia of the synovial tissue [28, 31]. When the deposition
in the tendons and tendon sheaths of the fingers is excessive,
these lesions cause "amyloid hand."
The main target of (32m amyloid-related destructive
arthropathy is large and medium-sized joints. The pathology
ranges from synovitis and effusions to erosions and destruction
[11, 20—23, 32] accompanied by stiffening and pain of the
involved joints.
As in CTS, the lesions can start unilaterally but in many cases
the contralateral joint soon becomes affected. Symptoms due to
involvement of shoulders and knees usually arise approxi-
mately 8 to 10 years after the start of RDT and very often
coincide with the manifestation of CTS. As a rule, the hips
subsequently become affected (that is, 12 to 15 years after the
start of RDT), culminating in pathologic fractures of the femoral
neck.
Spinal symptoms—especially destructive spondyloat-thropa-
thy—manifest at variable times. The spine can be affected
early, but more often it begins to deteriorate many years after
the start of RDT. Whether the thm amyloid found in affected
locations [23, 33—36] is a primary factor in the pathogenesis of
spondyloarthropathy in regular dialysis patients is still contro-
versial [37]. Kuntz et al have suggested that the deposition of
hydroxyapatite crystals in the intervertebral discs plays a
pathogenetic role in dialysis-related spondyloarthropathy [38].
There is no doubt, however, that j32m amyloid deposits were
responsible for the development of spinal neurologic complica-
tions in 3 reported cases [36, 39, 40]. Finally, in many cases,
fl2-microglobulin amyloidosis also affects the sternoclavicular
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joint. The deposits can be asymptomatic [41] or accompanied
by painful joint swelling [42].
Radiologic examination in f32m-amyloid-associated arthropa-
thy demonstrates erosions and marginal defects of the affected
bones, mainly at synovial insertion sites. A characteristic
finding is periarticular cystic bone lesions, which grow in
number and size with the continuation of RDT. Commonly
affected sites include the carpal bones, femoral and humoral
heads, acetabulum, tibial plateau, and distal radius [20—23, 29,
32]. Subchondral cysts in the knee, hip, and shoulder can
precede articular narrowing by 2 to 4 years [21]. Progression of
cystic bone defects in the femoral neck results in pathologic
fractures [11, 21, 32]. Extraosseous radiologic findings, which
include swelling of articular and periarticular soft tissue mainly
involving joint capsules, synovia, and tendons, can be visual-
ized and quantified by ultrasonography [43].
Distinguishing /32m-amyloid-related bone cysts from brown
tumors of secondary hyperparathyroidism is not always easy. If
radiologic signs of subperiosteal bone erosion are missing, and
bone cysts increase in size despite parathyroidectomy, one can
probably assume that DRA is present. Of further differential
diagnostic value is that hyperparathyroid cysts often appear in
the metaphysis and epiphysis of tubular bones, jaws, and ribs,
whereas the amyloid-related cysts are restricted to the vicinity
of synovial joints [20, 21, 23, 44]. One also should take into
account that cysts attributable to secondary hyperparathyroid-
ism rarely are located in carpal bones [45]. Finally, subchondral
bone cysts appear to be very specific for f32m amyloidosis.
Zingraaf and coworkers pointed out a close correlation between
the occurrence of subchondral bone cysts and histologic evi-
dence of J32m amyloidosis in the sternoclavicular joint [41].
Immunohistologic evaluation of biopsy and autopsy speci-
mens discloses f32m amloid deposits localized mainly in the
synovia of the affected joints. Amyloid also is detected in
material obtained from the bone cysts, either by cyst puncture
or during surgery for repair of pathologic fractures from cystic
bone lesions. In these patients with cystic bone lesions, the
amyloid deposits were found to be especially massive [11, 21,
32].
Using the radiologic and clinical criteria I have outlined, one
can conclude that the prevalence of osteoarticular lesions
attributable to /32m amyloid, like the prevalance of CTS,
increases with the duration of RDT; beyond 15 years, virtually
100% of hemodialysis patients have osteoarticular lesions [32].
Older patients are at a higher risk of being affected [27].
The salient radiologic and clinical feature of DRA is the
appearance of deposits in osteoarticular tissue. Deposition of
/32m amyloid outside these sites, in locations such as abdominal
fat, the gastrointestinal tract, lung, liver, heart, and endocrine
tissue, has been demonstrated in a limited number of patients
[28, 46—56]. Although the visceral amyloid deposits generally
are small and mainly perivascular, in a few patients, these
deposits can have significant clinical consequences, such as
cardiac or intestinal malfunction [47, 51—55]. Because of the
limitations in deposit size and distribution of extraskeletal j32m
amyloid, easily accessible regions such as abdominal subcuta-
neous fat and the rectum are not reliable biopsy target areas for
diagnosing 32m amyloidosis [22, 28, 48, 55—57].
Pat hophysiology
Beta,-microglobulin, an 11,800 dalton globular protein, con-
sists of 100 amino acids arranged in a single polypeptide chain.
As part of the human class-I major histocompatibility complex,
2m is expressed on the surface of all nucleated cells [58—60].
Also found as an intragranular protein within neutrophil gran-
ulocytes, it is released from these cells during degranulation
[61]. Experimental studies in hepatocytes showed that in these
cells f32m is a secretory protein; its synthesis and release are
modulated by alpha- and gamma-interferon [62].
After shedding from cellular surfaces or release from within
cells, J32m can be detected in the plasma. Plasma f32m is not
bound to other protein, and more than 90% circulates in
monomeric form [63]. Approximately 95% of f32m is eliminated
via glomerular filtration [64], thereafter undergoing almost
complete tubular absorption and metabolic degradation [65];
the remaining 5% is cleared at unknown extrarenal sites. Not
surprisingly, a close negative correlation between glomerular
filtration rate and the serum level of J32m has been demonstrated
[66]. The average daily synthesis of f32m in normal subjects is
approximately 200 mg. Measurements in 3 patients with various
degrees of severe renal insufficiency showed values of the same
order of magnitude [64].
Increased synthesis and release of /32m into the extracellular
space, as indicated by a rise in serum /32m levels, occurs in
inflammatory and malignant lymphoproliferative disease [67].
In vitro and in vivo studies indicate that increased synthesis and
release of /32m are mediated by cytokines: stimulatory effects
on synthesis and release in cultures of various cell types could
be ascribed to tumor necrosis factor (TNF), interleukin-2 (IL-
2), and interferon (INF) alpha and gamma [62, 68—70]. In vivo
application of recombinant INF alpha and gamma as well as of
TNF increased 132m serum levels [70, 71]. Findings regarding an
in vitro stimulatory effect of interleukin- 1 are controversial [62,
69, 70, 72]. In vivo, however, a stimulatory effect of IL-l via
induction of release of other cytokines such as INF and IL-2 is
predictable [73].
Retention and synthesis of f32m in patients on RDT. Serum
concentrations of /32m, normally ranging from 1 to 3 mg/liter,
can be elevated as high as 60-fold in patients receiving regular
hemodialysis who have no residual renal function [63]. The
retention of the precursor protein in terminal renal failure is an
absolute prerequisite for the development of /32m amyloidosis.
In view of the known effects of cytokines on /32m production
and with the growing evidence that hemodialysis induces an
inflammatory response, it is conceivable that the process of
hemodialysis itself might increase f32m synthesis and release,
thereby contributing to the accumulation of the amyloid precur-
sor protein. Activation of cells and the release of inflammatory
mediators during or following hemodialysis have been postu-
lated since the early l980s as part of the interleukin hypothe-
sis" [74]; the theory has been widely documented since. During
hemodialysis, blood cells can release several mediators includ-
ing IL-i [75—77], TNF [77], reactive oxygen species [78], and
prostaglandins [79]. Furthermore, complement activation oc-
curs on some dialysis membranes [80], which in turn induces
cellular monokine mRNA production, thereby preconditioning
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cells to an increased monokine release upon subsequent stim-
ulation [81]. Besides the dialysis membrane, acetate (as dialy-
sate buffer) and especially endotoxin in the dialysate induce
cellular monokine release [82, 83]. Some of these mechanisms
also might be operative in CAPD patients. Two reports suggest
that peritoneal dialysis itself is sufficient stimulus to induce
peritoneal activation of cells and cytokine release in asympto-
matic patients treated with continous ambulatory peritoneal
dialysis (CAPD) [84, 851.
Direct, experimental in-vitro data indicate that the inflamma-
tory response induced by hemodialysis could cause an in-
creased production of f32m. Recent studies demonstrated that
isolated peripheral blood lymphocytes (PBL) and peripheral
blood mononuclear cells (PBMC) harvested at the end of
hemodialysis with cellulosic membranes showed, respectively,
an increased expression of f32m RNA in culture [861 or higher
f32m concentrations in the culture supernatant [87] when com-
pared with control cells harvested before dialysis. When poly-
methylmethacrylate (PMNA) membranes were used, the /32m
concentration in PBMC supernatants did not increase. In addi-
tion to the release of inflammatory mediators, hemodialysis can
induce degranulation of neutrophil polymorphonuclear leuko-
cytes (PMNL) and release of proteases, depending on the type
of membrane used [88, 89]. It is conceivable but not yet proved
that the degranulation of neutrophil PMNL also involves /32m-
containing granules [61] and thereby also results in cellular
release of /32m.
Definitive in-vivo evidence for an increased synthesis of f32m
induced by hemodialysis is not available. Increases of fJ,m
serum levels ranging from 5% to 40% observed during hemodi-
alysis with cellulosic membranes impermeable for /32m [90—92]
were interpreted as an indication of increased production of
/32m [90]. Subsequently, however, 2 separate studies, one using
inulin space measurements [93] and the other using comparative
kinetics of myoglobin as a marker molecule of similar size [94],
showed that in hemodialysis with celiulosic membranes, the
intradialytic changes of serum concentrations of /32m are mainly
consequences of concomitant changes of extracellular volume.
Further support for this concept comes from the finding that
sham dialysis (without dialysate and hence without weight loss)
using cellulosic membranes for 2 to 4 hours does not change
f32m serum levels [94].
We determined overall f3.2m synthesis in 11 anuric chronic
hemodialysis patients and in S healthy volunteers in a kinetic
study using '31I-/32m [95]. The mean synthesis rate of 3.10
0.79 (SD) mg/kg/day of the patient group was higher than that of
2.4 0.67 mg/kg/day in healthy controls; the difference was not
significant, however. Within the patient group, those treated
with /32m-impermeable, "less biocompatible" cuprophane
membranes (n 5) had a higher mean synthetic rate than did
those (n = 5) treated with /'32m-permeable, "more biocompati-
ble" polysulfone membranes, 3.26 0.80 (SD) mg/kg/day
versus 2.66 0.46 mg/kg/day. The limited data preclude any
meaningful statistical analysis of the subgroups. More informa-
tion regarding the effect of dialyzer membrane would be gained
by comparing rates of synthesis of /32m before and after the use
of various membranes in the same individuals.
Processing of f32m and amyloido genesis. In addition to
retention and possibly increased synthesis of the precursor
protein, further mechanisms appear to be involved in the
pathogenesis of fJ2m amyloidosis. Although amyloid fibril-like
structures can be created in vitro from intact f32m [96], several
observations argue against simple precipitation as the sole
mechanism of amyloidogenesis in DRA: (1) the /32m serum level
does not correlate with the presence or absence of disease [96,
97]; (2) fragmented and polymerized f32m next to monomeric-
intact /32m was found to be a major constituent of the amyloid
[8, 98, 99]; (3) the predilection of /32m amyloid for osteoarticular
tissue with relative sparing of parenchymal organs, which
generally are involved in other types of amyloidosis, suggests
specific local mechanisms predisposing to amyloid deposition;
(4) the increased prevalence of DRA with age [27], and our own
observation that occasional patients are spared from DRA even
though they have had hemodialysis treatment with cellulosic
membranes for more than 15 years, suggests that additional
pathogenctic mechanisms of a more general nature exist.
In contrast to the initial findings of Gejyo [5, 6], Linke's
analysis of the amino-acid sequence of J32m-amyloid fibrils
revealed that these fibrils not only consisted of intact j32m, but
to a significant degree, also of p2m fragments, most of them
with lysine-specific cleavage [98, 99]. Ogawa also showed by
two-dimensional electrophoresis that in addition to intact fl2m,
a "novel f32m" with a reduced molecular weight occurred in
solubilized amyloid fibrils [100]. This "novel J32m" also was
detected in the plasma of long-term hemodialysis patients with
clinical manifestations of p2m-amyloid. These findings suggest
that alterations of the precursor molecule, such as limited
proteolysis, are involved in /32m amyloidogenesis; this hypoth-
esis is consistent with current concepts of the patbogenesis of
several other types of amyloid [101]. The cellular activation
with subsequent release of inflammatory mediators and prote-
ases induced by hemodialysis might be involved. Such cellular
activation preceding the limited proteolysis of /32m could take
place on the dialyzer membrane itself. Alternatively, resident or
blood-derived cells in the tissue (especially macrophages) acti-
vated by mediators released from circulating cells during dial-
ysis might participate in f32m proteolysis.
An intriguing modification of the proteolysis hypothesis was
suggested recently by Argues and colleagues [102]. They posit
that incompleteness of proteolysis of f32m is the prerequisite for
amyloid fibril formation and that complete proteolysis is pre-
vented by "amyloid-enhancing factors" such as the anti-pro-
tease amacroglobulin (a2m); further, they demonstrated the
presence of a2m in J32m amyloid deposits. If this hypothesis is
correct, the modulation of proteolysis by a2m-macroglobulin is
twofold; in addition to the proteolytic activity of enzymes
already synthesized, a2m also inhibits the protease production
of macrophages following specific receptor binding [104, 105].
Adding credence to Argilés' concept is the observation that, in
patients receiving RDT who have CTS, serum levels of a2m
were higher than they were in patients without amyloidosis who
had had RDT for just as long [106].
The predilection of fl2m amyloid deposits for osteoarticular
tissues, which are rich in collagen, and the close ultrastructural
association between 132m amyloid and collagen within these
tissues [12, 17, 31] suggest a high affinity of the precursor fJ2m
for collagen. Indeed, Homma et al showed that 132m binds to
various collagens in a dose-dependent manner [107]. Whether
this affinity for collagen is increased in hemodialysis patients
because of alterations in collagen composition is unknown.
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According to experimental findings by Kisilevsky and Snow,
the glycosaminoglycans (GAG) composition of the interstitial
matrix of the periarticular tissue also might be a local factor
favoring amyloid formation [1081. A relation between amyloid
deposition and GAGs also was suggested by ultrastructural and
immunohistochemical studies of J32m-amyloid deposits in he-
modialysis patients [13]. Nishi et al demonstrated that the
amyloid fiber bundles were surrounded by GAGs and con-
cluded that GAGs regulate the distribution and arrangement of
fibrils.
If proteolytic processing of the precursor molecule is a
prerequisite for fibril formation, one can reasonably assume
that the proteolytic processing takes place where the precursor
accumulates. Within the synovia, the predominant location of
articular f32m amyloid deposits, amyloid is found with and
without synovial infiltration by inflammatory cells [31]. The
prime suspects involved in f32m proteolysis therefore are the
synoviocytes. Their number in patients receiving long-term
hemodialysis treatment is significantly increased [311, and a
subtype (type A) morphologically and functionally displays
macrophage-like features [109]. This potential involvement of
the synoviocytes in fibril pathogenesis could be a further
predisposing factor for the preferential articular disposition of
2m amyloid. Whether the synoviocytes are activated and
proliferate because of the mere presence of f32m, or whether
inflammatory processes induced by hemodialysis are also in-
volved is not known.
Aluminum [1101 and iron [111] also have been proposed as
predisposing factors to the intraarticular accumulation of f32m.
The role of iron is controversial, and contradictory observa-
tions exist [23, 32]. The issue is complicated by the possibility
that the simultaneous increase of aluminum and iron deposits,
on the one hand, and of amyloid deposits, on the other, might
be a fortuitous association of two independent, time-related
complications of long-term hemodialysis therapy.
Therapeutic considerations
The experimental investigation of dialysis-related amyloido-
sis continues to pose many intriguing questions to the scientist.
But how does our current knowledge aid the clinician who has
to care for these patients? Let us consider some important
points that can be useful in clinical decision-making.
(1) Dialysis-related amyloid would not exist without accumu-
lation of the precursor.
(2) The possibility that the dialytic process promotes the
pathogenesis of DRA via regular induction of intermittent
inflammatory reactions is too great to be disregarded.
(3) A large, retrospective multicenter study showed that
long-term hemodialysis with a highly permeable acrylonitrile
membrane was superior to long-term hemodialysis with a
cuprophane membrane, in that the former was associated with
a lesser prevalence of clinical and radiologic manifestations of
DRA [27]. Although this study is otherwise very thorough and
critical, it is limited because it relied mainly on clinical and
radiologic criteria, and the number of patients at risk for 15
years was small. Nevertheless, the study results do support
points (1) and (2) for the following reasons: In contrast to
cuprophane, which is practically impermeable to 2m, acryloni-
trile permits a weekly removal of 400—600 mg of f32m [1121.
Even though this quantity is far less than the weekly synthesis
of approximately 1500 mg [95], its removal probably at least
slows the continous increase of the 2m burden. Furthermore,
in comparison to cuprophane, acrylonitrile is more "biocom-
patible," as it has a high adsorptive capacity for cytokines [113]
as well as endotoxins [114], and its use is accompanied by little
release of proteases from blood cells [88], low complement
activation [115], and little induction of phagocytic oxidative
metabolism [78].
(4) The multicenter study I just mentioned showed that age at
onset of RDT also affected the prevalence of chronic manifes-
tations of DRA [27]. Patients over the age of 40 at the initiation
of regular hemodialysis treatment carried a higher risk for the
development of bone amyloidosis than did younger patients.
(5) Successful, early kidney transplantation certainly pre-
vents DRA. Furthermore, in patients with already established
DRA, renal transplantation arrests the progression of radiologic
signs of DRA [1161 and produces an almost immediate abate-
ment of osteoarticular pain. The latter effect probably is mainly
due to the antiinflammatory action of steroids, but it also might
be caused partly by the termination of the induction of inflam-
matory activity by hemodialysis and the return of normal or
nearly normal renal function.
Let me suggest a cautious but, I believe, justified set of
policies based on these five points. Patients older than fifty,
whether or not they are candidates for transplantation, should
be dialyzed with the acrylonitrile membrane or a membrane
with comparable qualities, such as polysulfone or polyamide.
The same approach applies for younger patients who have little
chance of receiving a transplant. Patients with clinically estab-
lished DRA should be given a high priority for transplantation
so they won't become disabled. In view of the potential of
bacterial products to induce inflammatory processes during
hemodialysis, the dialysate should be sterile and pyrogen-free.
This measure especially applies when membranes with less
resistance to the passage of bacterial products from dialysate to
blood are used [117].
Should one use hemofiltration or continuous ambulatory
peritoneal dialysis (CAPD) to prevent or delay the manifesta-
tions of DRA? Even though hemofilters with "biocompatible"
membranes enable the weekly removal of approximately 1000
mg of f32m [118], wide use of hemofiltration will be prevented by
its prohibitive cost as long as commercial substitution fluid has
to be used. The weekly removal of approximately 300 mg of
f32m in CAPD patients is lower than that achieved with hemo-
dialysis with high-flux membranes [112]. Like hemodialysis,
CAPD can induce cellular activation and release inflammatory
mediators [84, 85]. Clinical reports of continuous progression of
DRA bone lesions after a change from hemodialysis to CAPD
[32] and of the occurrence of amyloid deposits in patients
treated exclusively by CAPD [119, 120] suggest that CAPD
might not be superior to hemodialysis in preventing DRA or in
delaying its onset. A conclusive comparative evaluation of the
prevalence of DRA in CAPD patients and regular hemodialysis
patients does not exist because of the small number of patients
with long-term exposure to CAPD.
The rationale for my recommendations certainly would be
strengthened and additional preventive measures could be
evaluated by prospective studies. So far, the prospective eval-
uation of strategies for preventing DRA has been hampered by
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the non-availability of an early and sensitive diagnostic proce-
dure that would be acceptable to patients and that would
indicate the presence of f32m amyloid anywhere in the body.
Amyloid-related clinical symptoms or radiologic findings are
late occurrences in the development of DRA, and biopsies of
non-selected, easily accessible tissues at best yield only chance
findings of amyloid [22, 28, 48, 55—57]. The two procedures that
most often yield positive results, synovial biopsies and the
aspiration of joint effusions [19, 22, 26], do not have the
potential of becoming routine diagnostic procedures in prospec-
tive trials. However, two recent reports are very promising.
They describe the diagnostic radionuclide tracing and imaging
of f32m-amyloid deposits by injections of either '231-labeled
serum amyloid P component (SAP) [1211 or 1311-labeled /32m
[1221. A minor constituent of j32m-amyloid, SAP accounts for
about 5% to 15% of the total amyloid mass [123]. Injection of
the radiolabeled molecule allowed the noninvasive detection of
amyloid deposits of the carpal-tunnel region and metacarpopha-
langeal joints of two long-term hemodialysis patients [121]. It is
not known, however, whether the scan also will detect minor,
asymptomatic, early stages of amyloid deposition. An alterna-
tive to scanning with radiolabled SAP is offered by the injection
of the radiolabeled precursor molecule j32m [122]. Using this
technique, we found localized tracer accumulation in the shoul-
ders, hands, knees, pelvis, and vertebral column in 23 of 30
patients on regular hemodialysis treatment longer than 5 years
[122]. Correlation of scan findings with available immunohistol-
ogy showed a very high sensitivity and specificity of the scan
for the detection of $2m-amyloid deposits. With the scan it is
possible to detect amyloid deposits before their presence is
indicated by clinical symptoms and/or radiologic alterations of
bones. This is shown in Figure 3, which depicts our results to
date in 49 patients.
Currently, this radiodiagnostic method offers a sensitive and
noninvasive way of demonstrating p2m deposits. It might not
only permit a more complete description of the prevalence of
f32m-amyloidosis but, by repeated scanning, it also might allow
one to assess the influence of different therapeutic strategies on
the appearance of amyloid deposits or on the fate of existing
deposits.
Questions and answers
DR. F. JOHN GENNARI (Professor of Medicine and Director,
Nephrology Division, University of Vermont College of Medi-
cine, Burlington, Vermont): It seems to me that CAPD patients
would be the appropriate controls for chronic hemodialysis
patients in studies on DRA. Are there comparisons? What are
the f32-microglobulin levels in CAPD patients? I am surprised
that this population has not been studied more completely.
DR. KocH: The populations with long-term exposure to
CAPD, that is, longer than 10 years, are very small, so no
conclusive comparison of the prevalence of DRA in CAPD
patients and regular hemodialysis patients is available. Never-
theless, the number of case reports with /32m-amyloid being
found in CAPD patients are increasing. Actually there exists
one study by Benz et al comparing the incidence of CTS in two
large populations of regular hemodialysis and CAPD patients
[124]. There were no significant differences, but no histologic
examinations for amyloid were performed. Regarding /32m
plasma levels in CAPD patients, plasma j32m is in the range of
that in hemodialysis patients provided renal function is compa-
rable.
Da. CHARLEs VAN YPER5ELE (Professor of Medicine, Renal
Unit, Cliniques Universitaires, St. Luc Universite de Louvain,
Louvain, Belgium): In our hands, adequate radiologic examina-
tion of the wrists and, more recently, ultrasonic quantitative
assessment of tendon thickness in the shoulders and the hips
provide early specific evidence for the diagnosis of DRA. Under
the circumstances, what is the place of isotopic imaging tech-
niques?
Da. KOCH: I totally agree regarding the usefulness of x-rays
and ultrasonography in the clinical situation. The isotopic
imaging techniques, since they are highly sensitive and specific
and in our hands enable us to prove the existence of amyloid
before characteristic skeletal alterations are visible, are excel-
lent research tools. This especially applies for their use in
prospective trials comparing the effect of different dialytic
treatment modalities on the development and progression of
DRA.
DR. VAN YPERSELE: 131I-3microglobu1in entails a 2 to 3 mCi
load that has radiation hazards unacceptable to Belgian ethics
committees. We should not forget that /32-microglobulin amy-
bid was demonstrated prior to the onset of dialysis [125]. It is
worth pointing out that the synovial deposition of amyboid is not
limited to /32-microglobulin amyloidosis but is a characteristic of
amyloidosis due to AL amyloid as well. Further, spleen depos-
its have been identified by Pepys and his colleagues, who relied
on 1231 serum amyloid P component imaging techniques [126].
DR. KOCH: At present the radiation dose of the '31I-f32m scan
technique is comparable to that of a barium enema x-ray
investigation of the colon. We therefore apply this technique
very restrictively but hope to be able to reduce the radiation
exposure by employing other isotopes. The serum amyloid P
(SAP) component scan developed by Pepys and coworkers
imparts less radiation exposure because the imaging of the
amyloid deposits takes place after 24 hours instead of 72 hours
with the 1311-f32m scan.
To my knowledge, there exists only a single reported patient
with proven /32m-amyloid prior to the onset of dialysis [125].
The patient was 69 years old and had long-standing, severe
renal insufficiency due to cortical necrosis. Histologically
proven splenic deposition of f32m-amyloid so far has been
reported in only 4 patients. In view of this very rare incidence,
the frequent positive splenic imaging with the SAP scan (12/35
RDT patients) reported by Pepys and coworkers is very sur-
prising [126].
DR. ANDREW REE5 (Professor of Nephrology, Royal Post-
graduate Medical School, London, United Kingdom): I would
like to focus on the specificity of the /32-microglobulin scans.
The SAP scan has been shown to be highly specific for amyloid
both by autoradiography and by the use of appropriate controls.
Is the same true for the 132m on scans? My second question
relates to the increase in RNA for IL-lfi. It appeared to be
transient, as there appears to be no increase in cells tested after
3 hours of dialysis. Was the increase in IL-1j3 message associ-
ated with synthesis of the protein, or were you just showing
changes in mRNA?
DR. KOCH: The WI/32m scan also is highly specific regarding
the imaging of f32m amyloid deposits. In all cases we have so far






with prior positive imaging. Inflammatory lesions of other
causes, such as active chronic polyarthritis and abscesses,
when they were present in the investigated hemodialysis pa-
tients, showed no positive imaging.
Regarding the demonstration of mRNA for IL-1/3 in mono-
nuclear cells of samples taken at the venous blood line of a
cellulosic dialyzer, this indeed was a transient phenomenon.
The disappearance of mRNA in samples taken during the later
course of hemodialysis suggests that the induction of mRNA for
IL-l13 is due to CSa, which preferably is generated during the
early part of hemodialysis, when the membrane is not yet
coated by protein. So far we only have looked for mRNA in
mononuclear cells lyzed after they had been kept for 30 minutes
at room temperature following harvesting. We are in the pro-
cess of studying whether these cells also synthesize and release
IL-lp.
DR. MICHEL GOLDMAN (Head, Department of Immunology,
Hôpital Erasme, Université Libre de Bruxelles, Brussels, Bel-
gium): If we consider the clinical data of Charles van Ypersele
together with your own laboratory data, it appears that the
incidence of amyloidosis is lower with the use of synthetic
membranes that are permeable to cytokine-inducing sub-
stances. The important factor therefore could be the comple-
ment activation induced by cellulosic membranes. Since this
%ofpts. N=13 N=21 N=9 N=6
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Fig. 3. '311-p2m accumulation in hemodialysis patients versus clinical and/or radiologic findings compatible with the diagnosis of J32m-amyloidosis.
Tracer accumulation and clinical/radiologic symptoms were graded according to the number of sites involved: 0, none; I, one or two sites; II, three
or four sites; III, five or six sites; and IV, more than six sites.
II III liv
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phenomenon can be prevented by reusing the membranes, does
the reuse procedure have any influence on the development of
dialysis-related amyloidosis?
DR. KOCH: I do not know of any study of the effect of
dialyzer reuse on the development of dialysis-related amyloi-
dosis. Whether complement is activated in a reused dialyzer
depends on the membrane-cleansing procedure applied before
reuse. Of course we have to realize that cell-membrane contact
and complement activation might not be the only mechanisms
involved in cytokine induction. We also have to consider that
bacteria-derived substances contained in the dialysate might
permeate the dialyzer membrane and induce cytokines on the
blood side.
DR. MICHAEL J. MIHATSCH (Chairman, Department of Pa-
thology, University of Basel, Base!, Switzerland): What is
known about the turnover and disappearance rate of 132m
amyloid in transplant patients?
DR. KOCH: So far there exists no direct evidence that f32m
amyloid deposits are reduced or disappear after successful
transplantation in RDT patients. The immediate and impressive
reduction in amyloid-related symptoms after transplantation
probably is due to the antiinflammatory effects of steroids.
Studies by Dr. van Ypersele also showed that there is no further
progression of the radiologic manifestations of DRA but also no
regression after successful transplantation. Pepys and cowork-
ers reported negative SAP scans in patients after transplanta-
tion despite histologically proven DRA before transplantation
[1261. This observation indeed suggests reduction of amyloid
mass after transplantation. An alternative explanation could be
a lack of newly formed amyloid fibrils with free ligands for SAP
binding.
DR. CHARLES M. MION (Professor of Nephro!ogy and Head,
Division of Nephrology, University of Montpellier, School of
Medicine, Montpellier, France): I believe that the residual renal
function in CAPD patients probably is extremely important in
retarding the development of Ø2m amyloidosis. Second, I have
seen carpal-tunnel syndrome with equal frequency in patients
treated with and without cuprophane membranes. Would you
comment?
DR. KOCH: I agree; residual renal function is generally better
preserved during the first years of CAPD, so the accumulation
of /32m, the amyloid precursor protein, might be reduced and
the development of 2m amyloidosis might be retarded.
Your observation of an equal frequency of CTS in patients
treated with cellulosic membranes and those treated with non-
cellulosic membranes does not disagree with the results of the
European multicenter study: Whereas there was a significant
effect of the choice of membrane on bone amyloidosis, radio-
logically determined, there was no effect on the prevalence of
CTS sufficiently severe to require surgery. A cautious interpre-
tation of these findings is that, in hemodialysis patients, thm
amyloid might not be the only cause of CTS.
DR. ARTURO BORSATTI (Professor of Nephro!ogy, Institute
of Internal Medicine, University of Padova, Padova, Italy):
Can a steady state of j32-microglobulin be achieved in dialysis
patients, or is there a constant increase of f32-microglobulin in
the blood? Can one remove the f32-microglobulin synthesized?
DR. KOCH: If you define a constant 132m plasma level as
indicative of a steady state, then chronic hemodialysis patients
are in a steady state as long as residual renal function and /32m
removal by dialytic treatment do not change. Accordingly, a
continuous increase of plasma fl2m is seen during the early
period of regular hemodialysis treatment when residual function
shows pronounced changes. In patients with very long times
spent on regular hemodialysis treatment, plasma levels tend to
decrease again, as shown by Charra et al [261 and supported by
our own experience. This finding has been interpreted as a
possible indication of increased j32m amyloid formation. Re-
garding your question whether 132m synthesis can be balanced
by removal, our own data suggest that this is not possible even
with high-flux hemodialysis or hemofiltration [95]. On the other
hand, it is conceivable that even a moderate reduction of 132m
accumulation might retard the development of DRA.
DR. CHRISTOPHER 0. WINEARLS (Consultant Nephrologist,
Renal Unit, Churchill Hospital, Oxford, United Kingdom): You
showed intriguing data on IL-1f3 in RNA expression in cells
harvested from the venous return of the dialyzer. Could you
comment on the synthesis rates, and on any differences pre- and
post-membrane?
DR. KOCH: We did not quantify the synthesis rate for IL-lj3
mRNA. The cells harvested from the arterial line contained no
or negligible amounts of mRNA, whereas there was a very
strong signal for mRNA in the cells taken from the venous
blood line at the same time.
DR. WINEARL5: Can you reassure us that the cell populations
were the same in the arterial and venous lines?
DR. KOCH: The assayed cell populations of the venous and
arterial sample were different. The mononuclear cells harvested
from the venous sample by Ficolllllypaque centrifugation sep-
aration were contaminated by as much as 40% with granulo-
cytes, whereas by the same technique we gained almost pure
mononuclear cells from the arterial sample. We attribute this
difference to a change of specific gravity of the granulocytes
after they pass the dialyzer. However, since granulocytes can
only express very small amounts of IL-l/3, we are very sure that
we measured the mRNA of mononuclear cells in the venous
sample.
DR. WINEARLS: What explains the speed with which the
RNA was expressed?
DR. KOCH: Before lysis of the cells for mRNA measurement,
the samples were kept for 30 minutes at room temperature. So
there was some time allotted for mRNA synthesis. The speed of
synthesis might not have been exceptionally high.
DR. ALEX M. DAVISON (Consultant and Renal Physician,
Department of Renal Medicine, St. James's University Hospi-
tal, Leeds, United Kingdom): You mentioned some of the
possible reasons for the distribution of p2m amyloid. Would you
expand your thoughts on this?
DR. KOCH: The predilection of /32m amyloid for synovial
tissue is very striking. This affinity might be due to a high
affinity of J32m for collagen. When one studies synovial /32m
amyloid deposits with the electron microscope, one almost
always finds the amyloid fibrils very closely arranged to colla-
gen fibrils. In this context it may be of importance that Homma
recently showed that f32m binds to various collagens in a
dose-dependent manner [107]. Some cells within the synovia
display macrophage-like functions and therefore might be in-
volved in proteolytic processing of 32m, which could be a
prerequisite for local amyloid fibril formation.
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Another local predisposing factor might be glycosoaminogly-
cans (GAGs) which, according to experimental findings of
Kisilevsky and Snow, are operative in amyloid fibril formation
[1081. Using tissue obtained from hemodialysis patients with
DRA, Nishi et al showed that 32m amyloid fibni bundles often
are surrounded by GAGs [13]. These researchers concluded
that GAGs exert a regulatory effect on the distribution and
arrangement of amyloid fibrils.
DR. JORDAN J. COHEN (Dean, School of Medicine, State
University of New York at Stony Brook, Stony Brook, New
York): You noted that there is a poor correlation between the
amount of /32-microglobulin amyloid and the amount of collagen
seen histologically. In fact, even in the patient presented today,
carpal-tunnel tissue from one side contained 32-microglobulin
amyloid, but on the other side /32m-amyloid was undetectable.
This discrepancy raises the possibility that the presence of 132-
microglobulin is an epiphenomenon. Is it possible that /2-
microglobulin is not involved in the pathogenesis but is some-
how being captured by the collagen, and that something else
triggers the mass of collagen that produces the symptoms of
carpal-tunnel syndrome?
DR. KOCH: This is a very good point. Whereas in some
patients the amyloid deposits are very massive and without
doubt cause local damage, for instance compression of the
median nerve, in other cases one finds only minute amounts of
amyloid but masses of collagen within the carpal tunnel tissue.
So there is the suspicion that the pathogenesis not only involves
132m-amyloid but also alterations of collagen metabolism.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Re-
garding pathogenesis, an IL-i receptor antagonist recently has
been developed and is being used in animal and human inves-
tigation. Has this antagonist been used in an effort to evaluate
the effects of dialysis-induced IL-i release on f32-microglobulin
production? Also, is there an animal model for the syndrome?
Recognizing the long time required for the syndrome to develop
in humans, one could employ exogenous administration of
132-microglobulin in association with dialysis to study the patho-
genesis of the syndrome.
DR. KocH: I do not know of any experiments studying the
effect of IL- 1 receptor antagonists on IL-i induction during
hemodialysis. So far there also do not exist animal models with
132m amyloidosis. I assume it would be necessary to dialyze
anuric animals for prolonged times. The additional infusion of
grams of f32m might speed up the development of f32m amyloi-
dosis.
DR. MICHEL OLMER (Chief, Nephrology Unit, Hôpital de Ia
Conception, Marseille, France): I am interested in whether the
use of pyrogen-free dialysate is associated with /32-microglob-
ulin deposition. In Marseille, we find amyloid deposits only in
patients treated with nonsterile dialysate.
DR. KocH: Bacteria-derived substances contained in the
dialysate can permeate certain dialyzer membranes and thereby
could induce cytokines such as IL-1f3 and tumor necrosis factor
(TNF) on the blood side. The involvement of such a chain of
events in the pathogenesis of DRA is conceivable but not
proven. The only clinical report supporting this concept is your
own work, which showed that the use of a dialysate with a very
low endotoxin content was accompanied by a lower incidence
of CTS [127]. However, as we discussed before, CTS is not
definite proof of the presence of amyloid.
Da. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Are there exper-
imental data regarding the pharmacologic inhibition of f2-
microglobulin synthesis?
DR. KOCH: Considering our own studies in uremic patients,
one has to assume that at least 75% of their /32m synthesis is due
to normal cell turnover. To inhibit 132m synthesis significantly,
one would have to suppress normal cell turnover. This would
necessitate the application of cytostatic drugs. I do not think
this is advisable in RDT patients who already suffer from a
multitude of immune defects.
DR. BRUNO BAGGIO (Associate Professor of Nephrology,
Institute of Internal Medicine, Division of Nephrology, Pa-
dova, Italy): Do you think that the plasma oxalate level and, in
particular, its abrupt variation during the interdialytic period
could play a role in dialysis-related amyloid syndrome?
DR. KOCH: I do not know of any data suggesting a relation
between plasma or tissue oxalate levels and DRA. We used the
1311-J32m scan to study a patient being treated with regular
hemodialysis who suffered from primary oxalosis. None of his
massive tissue oxalate deposits appeared positive with the scan.
Da. MIHATSCH: Beta2-microglobulin amyloid is always de-
posited in close association with collagen. The specificity of the
132 deposition might be related to the specific type of collagen.
Are there data regarding cytokines in synovial fluid and how
they might influence this binding?
DR. KocH: Your question concerning a preference of 132m for
a specific collagen certainly merits investigation. The same
applies for cytokine levels in joints with synovial f32m amyloid
deposits. Elevated levels would indicate local inflammatory
processes. I am sorry that I cannot be more specific.
DR. MICHAEL H. RAMBAUSEK (Department of Nephrology,
University of Heidelberg, Heidelberg, Germany): Beta2-micro-
globulin is part of the HLA system. This fact raises the question
of whether there is any genetic predisposition for the develop-
ment of dialysis-related amyloid disease.
DR. KocH: So far no data suggest a genetic predisposition for
DRA. The very high prevalence of DRA in long-term hemodi-
alysis patients actually argues against a major role for genetic
factors.
DR. JOHN F. DONOHOE (Consultant Nephrolo gist, Depart-
ment of Nephrology, Beaumont Hospital, Dublin, Ireland):
What is known of the relative prevalence or incidence of DRA
between the United States and Europe? Are there known
differences within Europe, that is, north versus south? If these
data are available, what are the implications regarding the
pathogenesis of DRA?
DR. KOCH: I am afraid that currently no representative data
are available that permit a comparison between the incidence of
DRA in the United States and Europe. The major obstacles
obviously are the lack of standardization of diagnostic criteria
and incomplete information concerning possibly relevant back-
ground conditions such as dialysate quality, application of
reuse, etc.
DR. LEENDERT A. VAN Es (Professor of Medicine, Depart-
ment of Nephrology, Leiden University Hospital, Leiden, The
Netherlands): Is the magnitude of the renal elimination of
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/3.2-microglobulin based on the measurement of arteriovenous
differences across the kidney in humans?
Dx. KOCH: Yes; by measuring renal arteriovenous differ-
ences of f32m concentrations in patients with normal renal
function, we have found that this difference is equal to or
slightly higher than that of inulin. This suggests that /32m is
freely filterable in the glomerulus. Similar findings are known
from animal studies.
Dx. MADIAS: Has your scanning technique with radiolabeled
fl2m suggested a greater systemic (that is, non-osteoarticular)
deposition of /3microglobulin than clinically suspected?
Dx. KOCH: No, our experience with the "I-j32m scan does
not suggest a very significant systemic deposition of /32m
amyloid outside osteoarticular tissues. Histologically proven
non-osteoarticular deposits in the majority of reported patients
were found to be minute and therefore might not be detected by
the scan.
Dx. MION: Would you comment on recent observations
showing early synovial deposits in dialysis patients [128]? What
is the sensitivity of the various scans in the detection of these
early deposits?
Dx. KOCH: Obviously, our scan is not able to detect micro-
scopic amyloid deposits. Nevertheless, it enabled us to spot
amyloid deposits in patients who had been treated with dialysis
for less than 6 years and who had no clinical or radiologic
indications of DRA.
Dx. WINEARLS: MayI comment on the SAP scans? Professor
Pepys' group at the Hammersmith Hospital recently completed
an evaluation of this technique in hemodialysis patients [126].
The principal findings were: (I) there is focal localization of
tracer at sites where histologic examination confirms amyloid
deposition but, apart from the spleen, no evidence of visceral
involvement; (2) the scans do not always detect fJ2m-amyloid in
deep sites; and (3) scans in four patients with a history of
dialysis amyloid proven histologically, who had had successful
renal transplants, were negative, suggesting that accumulation
of amyloid had at least been arrested.
Dx. KOCH: I agree regarding the very limited systemic
accumulation of j32m amyloid. Regarding f32m amyloid in deep
sites, the 1311-f32m scan proved to be very effective in imaging
amyloid deposits located in the hip joints. We have no post-
transplant experience with the scan, because administered j32m
is eliminated too rapidly by glomerular filtration when renal
function is restored; thus our scan cannot be applied in this
setting.
Dx. COHEN: How practical is it to maintain sterile dialysate?
Does it increase the cost of the procedure excessively? Would
you recommend using sterile dialysate routinely for all patients?
Dx. KOCH: In our experience with a well-designed and
carefully serviced reverse-Osmosis unit and good machine ster-
ilization, we can produce dialysate with a very low endotoxin
content, as low as 50 to 100 pg/mi.
A further improvement could be achieved by placing polysul-
fone or polyamide hemofilters in the dialysate line downstream
from the machine. Hemofilters made of these membranes reject
and adsorb bacteria-derived products and can be reused as long
as the cleaning procedure is performed with sterile and pyro-
gen-free water and also includes back-filtration.
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